Nuria Segarra

Nuria Segarra

Auto-generated profile, based on publicly available information

Nuria Segarra

Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, SPAIN

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2015 in Frontiers in Psychology
Verified
Journal Article
Open access
GAGonzalo Arrondo
Gonzalo Arrondo
NSNuria Segarra
Nuria Segarra
AMAntonio Metastasio
Antonio Metastasio
HZHisham Ziauddeen
Hisham Ziauddeen
JSJennifer Spencer
Jennifer Spencer
GMGraham K. Murray
Graham K. Murray
In the research domain framework (RDoC), dysfunctional reward expectation has been proposed to be a cross-diagnostic domain in psychiatry, which may contribute to symptoms common to various neuropsychiatric conditions, such as anhedonia or apathy/avolition. We used a modified version of the Monetary Incentive Delay (MID) paradigm to obtain functional MRI images from 22 patients with schizophrenia, 24 with depression and 21 controls. Anhedonia and other symptoms of depression, and overall positive and negative symptomatology were also measured. We hypothesized that the two clinical groups would have a reduced activity in the ventral striatum when anticipating reward (compared to anticipation of a neutral outcome) and that striatal activation would correlate with clinical measures of motivational problems and anhedonia. Results were consistent with the first hypothesis: two clusters in both the left and right ventral striatum were found to differ between the groups in reward anticipation. Post-hoc analysis showed that this was due to higher activation in the controls compared to the schizophrenia and the depression groups in the right ventral striatum, with activation differences between depression and controls also seen in the left ventral striatum. No differences were found between the two patient groups, and there were no areas of abnormal cortical activation in either group that survived correction for multiple comparisons. Reduced ventral striatal activity was related to greater anhedonia and overall depressive symptoms in the schizophrenia group, but not in the participants with depression. Findings are discussed in relation to previous literature but overall are supporting evidence of reward system dysfunction across the neuropsychiatric continuum, even if the specific clinical relevance is still not fully understood. We also discuss how the RDoC approach may help to solve some of the replication problems in psychiatric fMRI research.

28 December 2015 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
NSNuria Segarra
Nuria Segarra
AMAntonio Metastasio
Antonio Metastasio
HZHisham Ziauddeen
Hisham Ziauddeen
JSJennifer Spencer
Jennifer Spencer
NRNiels R Reinders
Niels R Reinders
GMGraham K Murray
Graham K Murray
Alterations in reward processes may underlie motivational and anhedonic symptoms in depression and schizophrenia. However it remains unclear whether these alterations are disorder-specific or shared, and whether they clearly relate to symptom generation or not. We studied brain responses to unexpected rewards during a simulated slot-machine game in 24 patients with depression, 21 patients with schizophrenia, and 21 healthy controls using functional magnetic resonance imaging. We investigated relationships between brain activation, task-related motivation, and questionnaire rated anhedonia. There was reduced activation in the orbitofrontal cortex, ventral striatum, inferior temporal gyrus, and occipital cortex in both depression and schizophrenia in comparison with healthy participants during receipt of unexpected reward. In the medial prefrontal cortex both patient groups showed reduced activation, with activation significantly more abnormal in schizophrenia than depression. Anterior cingulate and medial frontal cortical activation predicted task-related motivation, which in turn predicted anhedonia severity in schizophrenia. Our findings provide evidence for overlapping hypofunction in ventral striatal and orbitofrontal regions in depression and schizophrenia during unexpected reward receipt, and for a relationship between unexpected reward processing in the medial prefrontal cortex and the generation of motivational states.

1 February 2008 in Schizophrenia Research
Verified
Journal Article
Closed access
OPOscar Pino
Oscar Pino
GGGeorgina Guilera
Georgina Guilera
JRJ. Emilio Rojo
J. Emilio Rojo
JGJuana Gómez-Benito
Juana Gómez-Benito
MBMiquel Bernardo
Miquel Bernardo
JRJavier Rejas
Javier Rejas

1 March 2011 in European Psychiatry
Verified
Journal Article
Closed access
NSN. Segarra
N. Segarra
MBMiquel Bernardo
Miquel Bernardo
FGF. Gutierrez
F. Gutierrez
AJA. Justicia
A. Justicia
EFE. Fernadez-Egea
E. Fernadez-Egea
RKR.S.E. Keefe
R.S.E. Keefe
Neurocognitive impairment is a core feature of schizophrenia and is closely associated with functional outcome. The importance of cognitive assessment is broadly accepted today, and an easy-to-use, internationality validated cognitive assessment tool is needed by researchers and in daily clinical practice. The Brief Assessment of Cognition in Schizophrenia (BACS) has been validated in English, French, Japanese and Italian. It is as sensitive to cognitive dysfunction as a standard test battery, with the advantage of requiring less than 35 minutes to complete. In our study, we tested the psychometric characteristics of a Spanish version of the BACS in 117 patients with schizophrenia-spectrum disorders and 36 healthy controls. All BACS cognitive subtests discriminated between patients and controls (P< .001), and the concurrent validity between the BACS and a traditional neuropsychological test battery was similar to that reported in other languages. We conclude that the BACS can facilitate the comparison of the cognitive performance of patients with schizophrenia in many different countries.

1 February 2010 in Schizophrenia Research
Verified
Journal Article
Closed access
EREmilio Rojo
Emilio Rojo
OPOscar Pino
Oscar Pino
GGGeorgina Guilera
Georgina Guilera
JGJuana Gómez-Benito
Juana Gómez-Benito
SPScot E. Purdon
Scot E. Purdon
JRJavier Rejas
Javier Rejas

1 April 2009 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
GGGeorgina Guilera
Georgina Guilera
OPOscar Pino
Oscar Pino
JGJuana Gómez-Benito
Juana Gómez-Benito
JRJ Emilio Rojo
J Emilio Rojo
Eduard VietaEduard Vieta
Eduard Vieta
TFthe Spanish Working Group in Cognitive Function
the Spanish Working Group in Cognitive Function
Background: The relevance of persistent cognitive deficits to the pathogenesis and prognosis of bipolar disorders (BD) is understudied, and its translation into clinical practice has been limited by the absence of brief methods assessing cognitive status in Psychiatry. This investigation assessed the psychometric properties of the Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S) for the detection of cognitive impairment in BD. Methods: After short training, psychiatrists at 40 outpatient clinics administered the SCIP three times over two weeks to a total of 76 consecutive type I BD admissions. Experienced psychologists also administered a comprehensive battery of standard neuropsychological instruments to clinical sample and 45 healthy control subjects. Results: Feasibility was supported by a brief administration time (approximately 15 minutes) and minimal scoring errors. The reliability of the SCIP was confirmed by good equivalence of forms, acceptable stability (ICC range 0.59 to 0.87) and adequate internal consistency (Chronbach's alpha of 0.74). Construct validity was granted by extraction of a single factor (accounting 52% of the variance), acceptable correlations with conventional neuropsychological instruments, and a clear differentiation between bipolar I and normal samples. Efficiency was also provided by the adequate sensitivity and specificity. Limitations: The sample size is not very large. The SCIP and the neurocognitive battery do not cover all potentially relevant cognitive domains. Also, sensitivity to change remains unexplored. Conclusion: With minimal training, physicians obtained a reliable and valid estimate of cognitive impairment in approximately 15 minutes from an application of the SCIP to type I BD patients.